231 related articles for article (PubMed ID: 33507500)
1. Benefit of Early Add-on of Linagliptin to Insulin in Japanese Patients With Type 2 Diabetes Mellitus: Randomized-Controlled Open-Label Trial (TRUST2).
Katsuno T; Shiraiwa T; Iwasaki S; Park H; Watanabe N; Kaneko S; Terasaki J; Hanafusa T; Imagawa A; Shimomura I; Ikegami H; Koyama H; Namba M; Miyagawa JI;
Adv Ther; 2021 Mar; 38(3):1514-1535. PubMed ID: 33507500
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of linagliptin in subjects with long-standing type 2 diabetes mellitus (>10 years): evidence from pooled data of randomized, double-blind, placebo-controlled, phase III trials.
Lajara R; Aguilar R; Hehnke U; Woerle HJ; von Eynatten M
Clin Ther; 2014 Nov; 36(11):1595-605. PubMed ID: 25236917
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetic, pharmacodynamic, and tolerability profiles of the dipeptidyl peptidase-4 inhibitor linagliptin: a 4-week multicenter, randomized, double-blind, placebo-controlled phase IIa study in Japanese type 2 diabetes patients.
Horie Y; Kanada S; Watada H; Sarashina A; Taniguchi A; Hayashi N; Graefe-Mody EU; Woerle HJ; Dugi KA
Clin Ther; 2011 Jul; 33(7):973-89. PubMed ID: 21723606
[TBL] [Abstract][Full Text] [Related]
4. A Randomized Controlled Study Comparing a DPP4 Inhibitor (Linagliptin) and Basal Insulin (Glargine) in Patients With Type 2 Diabetes in Long-term Care and Skilled Nursing Facilities: Linagliptin-LTC Trial.
Umpierrez GE; Cardona S; Chachkhiani D; Fayfman M; Saiyed S; Wang H; Vellanki P; Haw JS; Olson DE; Pasquel FJ; Johnson TM
J Am Med Dir Assoc; 2018 May; 19(5):399-404.e3. PubMed ID: 29289540
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and tolerability of linagliptin added to a sulfonylurea regimen in patients with inadequately controlled type 2 diabetes mellitus: an 18-week, multicenter, randomized, double-blind, placebo-controlled trial.
Lewin AJ; Arvay L; Liu D; Patel S; von Eynatten M; Woerle HJ
Clin Ther; 2012 Sep; 34(9):1909-19.e15. PubMed ID: 22939034
[TBL] [Abstract][Full Text] [Related]
6. Effect of Linagliptin on Glycemic Control in Chinese Patients with Newly-Diagnosed, Drug-Naïve Type 2 Diabetes Mellitus: A Randomized Controlled Trial.
Wu W; Li Y; Chen X; Lin D; Xiang S; Shen F; Gu X
Med Sci Monit; 2015 Sep; 21():2678-84. PubMed ID: 26350766
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and Cardiovascular Safety of Linagliptin as an Add-On to Insulin in Type 2 Diabetes: A Pooled Comprehensive Post Hoc Analysis.
Zinman B; Ahrén B; Neubacher D; Patel S; Woerle HJ; Johansen OE
Can J Diabetes; 2016 Feb; 40(1):50-7. PubMed ID: 26474870
[TBL] [Abstract][Full Text] [Related]
8. [The efficacy and safety of linagliptin in elderly patients with type 2 diabetes: a pooled analysis of eight placebo-controlled clinical trials].
Guo XH; Feng ZK; Xu LH
Zhonghua Nei Ke Za Zhi; 2017 Aug; 56(8):588-594. PubMed ID: 28789492
[No Abstract] [Full Text] [Related]
9. Linagliptin improves glycemic control after 1 year as add-on therapy to basal insulin in Asian patients with type 2 diabetes mellitus.
Sheu WH; Park SW; Gong Y; Pinnetti S; Bhattacharya S; Patel S; Seck T; Woerle HJ
Curr Med Res Opin; 2015 Mar; 31(3):503-12. PubMed ID: 25629790
[TBL] [Abstract][Full Text] [Related]
10. Long-Term Efficacy and Safety of Linagliptin in a Japanese Population with Type 2 Diabetes Aged ≥ 60 Years Treated with Basal Insulin: A Randomised Trial.
Araki E; Unno Y; Tanaka Y; Sakamoto W; Miyamoto Y
Adv Ther; 2019 Oct; 36(10):2697-2711. PubMed ID: 31482511
[TBL] [Abstract][Full Text] [Related]
11. Linagliptin, a dipeptidyl peptidase-4 inhibitor in development for the treatment of type 2 diabetes mellitus: a Phase I, randomized, double-blind, placebo-controlled trial of single and multiple escalating doses in healthy adult male Japanese subjects.
Sarashina A; Sesoko S; Nakashima M; Hayashi N; Taniguchi A; Horie Y; Graefe-Mody EU; Woerle HJ; Dugi KA
Clin Ther; 2010 Jun; 32(6):1188-204. PubMed ID: 20637971
[TBL] [Abstract][Full Text] [Related]
12. Linagliptin monotherapy in type 2 diabetes patients for whom metformin is inappropriate: an 18-week randomized, double-blind, placebo-controlled phase III trial with a 34-week active-controlled extension.
Barnett AH; Patel S; Harper R; Toorawa R; Thiemann S; von Eynatten M; Woerle HJ
Diabetes Obes Metab; 2012 Dec; 14(12):1145-54. PubMed ID: 22974280
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of linagliptin to improve glucose control in older people with type 2 diabetes on stable insulin therapy: A randomized trial.
Ledesma G; Umpierrez GE; Morley JE; Lewis-D'Agostino D; Keller A; Meinicke T; van der Walt S; von Eynatten M
Diabetes Obes Metab; 2019 Nov; 21(11):2465-2473. PubMed ID: 31297968
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of linagliptin in subjects with type 2 diabetes mellitus and poor glycemic control: pooled analysis of data from three placebo-controlled phase III trials.
Del Prato S; Taskinen MR; Owens DR; von Eynatten M; Emser A; Gong Y; Chiavetta S; Patel S; Woerle HJ
J Diabetes Complications; 2013; 27(3):274-9. PubMed ID: 23403068
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor linagliptin in black/African American patients with type 2 diabetes: Pooled analysis from eight Phase III trials.
Thrasher J; Kountz DS; Crowe S; Woerle HJ; von Eynatten M
Postgrad Med; 2015 Jun; 127(5):419-28. PubMed ID: 25840727
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of evogliptin treatment in patients with type 2 diabetes: A multicentre, active-controlled, randomized, double-blind study with open-label extension (the EVERGREEN study).
Kim G; Lim S; Kwon HS; Park IB; Ahn KJ; Park CY; Kwon SK; Kim HS; Park SW; Kim SG; Moon MK; Kim ES; Chung CH; Park KS; Kim M; Chung DJ; Lee CB; Kim TH; Lee MK
Diabetes Obes Metab; 2020 Sep; 22(9):1527-1536. PubMed ID: 32319168
[TBL] [Abstract][Full Text] [Related]
17. Linagliptin provides effective, well-tolerated add-on therapy to pre-existing oral antidiabetic therapy over 1 year in Japanese patients with type 2 diabetes.
Inagaki N; Watada H; Murai M; Kagimura T; Gong Y; Patel S; Woerle HJ
Diabetes Obes Metab; 2013 Sep; 15(9):833-43. PubMed ID: 23565760
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of linagliptin in Asian patients with type 2 diabetes mellitus inadequately controlled by metformin: A multinational 24-week, randomized clinical trial.
Wang W; Yang J; Yang G; Gong Y; Patel S; Zhang C; Izumoto T; Ning G
J Diabetes; 2016 Mar; 8(2):229-37. PubMed ID: 25753488
[TBL] [Abstract][Full Text] [Related]
19. Comparative efficacy and safety of gemigliptin versus linagliptin in type 2 diabetes patients with renal impairment: A 40-week extension of the GUARD randomized study.
Han SY; Yoon SA; Han BG; Kim SG; Jo YI; Jeong KH; Oh KH; Park HC; Park SH; Kang SW; Na KR; Kang SW; Kim NH; Jang Y; Kim B; Shin S; Cha DR
Diabetes Obes Metab; 2018 Feb; 20(2):292-300. PubMed ID: 28719008
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of linagliptin as add-on therapy to insulin in Chinese patients with type 2 diabetes mellitus: A randomized, double-blind, placebo-controlled trial.
Yang W; Xu X; Lei T; Ma J; Li L; Shen J; Ye B; Zhu S; Meinicke T
Diabetes Obes Metab; 2021 Feb; 23(2):642-647. PubMed ID: 33074590
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]